King Fahad Armed Forces Hospital Begins Trial of New Bioadaptive Angioplasty Procedure for Heart Disease Treatment
King Fahad Armed Forces Hospital is the first in the Kingdom of Saudi Arabia to begin clinical research and offer a new type of angioplasty procedure with the DynamX® Bioadaptor, a novel coronary implant designed to restore vessel function in patients with coronary artery disease (CAD).
TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
Elixir Medical announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus versus a second-generation, durable polymer drug-eluting stent (DES).
Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023
Elixir Medical will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospective, multicenter, single-blind study, as part of The Innovation Program at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco
Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval
“Our submission for approval in Japan is an exciting milestone for the company and industry,” said Motasim Sirhan, CEO of Elixir Medical.
Job Post Template
Major Duties and Responsibilities Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla […]
Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial
The trial, which includes 2,400 patients from 20 sites across Sweden, compares DynamX Bioadaptor to Resolute Onyx.
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s Dynamx Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
Clinical data demonstrates Dynamx Bioadaptor restores vessel motion and function with better effectiveness than competitors.
Elixir Medical Expands Leadership Team with Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing
Nepogodiev possesses more than 20 years of leadership experience in successfully developing new markets and therapies in interventional cardiology, structural heart, and endovascular businesses worldwide.
DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study
A study in the latest issue of Cardiovascular Revascularization Medicines hows that the DynamX™ Coronary Bioadaptor System, when uncaged, enabled rotational motion similar to natural vessels.
Elixir Medical Strengthens its Commercial Capabilities with the Addition of Ahram as Executive Vice President, International
Ahram possesses more than 25 years of leadership experience and successes in building new markets and accelerating commercialization for novel medical devices across Asia, Europe, and the Middle East.